RCT: Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer.

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer – Journal of Clinical Oncology

Original Study: ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer – Journal of Clinical Oncology

Commentary on Twitter

🆕 #JCO #ClinicalTrialUpdate: ARCHES trial – 📈 Enzalutamide + ADT improved OS in men with metastatic horomone-sensitive #ProstateCancer 👉 https://t.co/FQ1lViCTZz #PCSM @AarmstrongDuke pic.twitter.com/fLs6PdFYlr

— Journal of Clinical Oncology (@JCO_ASCO) April 27, 2022